PPARgamma (C15) Antibody-Delta Biolabs

Product Info
Background	Peroxisome proliferator-activated receptors (PPAR) are members of the steroid nuclear receptor superfamily (1). The mammalian PPARs include three subtypes PPARalpha, PPARbeta, and PPARgamma. PPARs have been found to regulate fatty acid oxidation, fat cell development, lipoprotein metabolism, and glucose homeostasis (2). Recent studies have found that PPARs can affect the pathogenesis and development of tumors (3). PPARgamma and PPARbeta have been specifically implicated in tumorigenesis (3). PPARalpha is the focus of research studying its function in fatty acid beta-oxidation, lipid metabolism, and vascular inflammation (4). PPARbeta also plays a key role in the activation of keratinocytes during the inflammatory reaction associated with a skin injury (5). Of the three subtypes of PPARs, PPARgamma is the most widely studied. PPARgamma has been implicated in various human chronic diseases such as diabetes mellitus, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, and Alzheimer�s disease (6).
Origin	PPARgamms (C15) is provided as an affinity purified rabbit polyclonal antibody, raised against a peptide mapping near the carboxy terminus of human PPARgamma.
Product Details	Each vial contains 0.200 mg/ml of affinity purified rabbit IgG, PPARgamma (C15) DB134, in 1 ml PBS containing 0.1 % sodium azide and 0.2% gelatin.
Competition Studies	A blocking peptide is also available, DB134P, for use in competition studies. Each vial contains 0.100 mg of peptide in 0.5 ml PBS with 0.1% sodium azide and 0.100 mg BSA.
Immunogen	A synthetic peptide mapping near the carboxy terminus of human PPARgamma.
Specificity	PPARgamma (C15) DB134 will recognize mouse, rat, human, hamster, chicken, dog, bovine, and pig PPARgamma1 and PPARgamma2.
Use	Recommended for western blotting, starting dilution 1:400. Immunohistochemistry: not yet tested. Immunoprecipitation: not yet tested
Storage	Store this product at 4� C, do not freeze. The product is stable for one year from the date of shipment.
References	1.Bocos C, Gottlicher M, Gearing K, Banner C, Enmark E, Teboul M, Crickmore A, and Gustafsson JA. 1995. Fatty acid activation of peroxisome proliferator-activated receptor (PPAR). J Steroid Biochem Mol Biol 53(1-6):467-473. 2.Li AC, and Glass CK. 2004. PPAR and LXR-dependent pathways controlling lipid metabolism and development of atherosclerosis. J Lipid Res. 3.Nahle Z. 2004. PPAR trilogy from metabolism to cancer. Curr Opin Clin Nutr Metab Care. 7(4):397-402. 4.van Raalte DH, Li M, Pritchard PH, Wasan KM. 2004. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm Res. 21(9): 1531-1538. 5.Tan NS, Michalik L, Desvergne B, Wahli W. 2003. Peroxisome proliferator-activated receptor (PPAR)-beta as a target for wound healing drugs: what is possible? Am J Clin Dermatol. 4(8): 523-530. 6.Takano H, Hasegawa H, Zou Y, Komuro I. 2004. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr Pharm Des. 10(22): 2779-2786.